⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21645228 | 1.00 | — | — | |
| SCHEMBL21645160 | 1.00 | — | — | |
| SCHEMBL5968091 | 0.82 | — | — | |
| SCHEMBL1768335 | 0.78 | — | — | |
| SCHEMBL11153518 | 0.78 | — | — | |
| SCHEMBL1768332 | 0.78 | — | — | |
| SCHEMBL7392053 | 0.78 | — | — | |
| SCHEMBL18030812 | 0.77 | PGD (0.55) | — | |
| Hydrochloric Acid SCHEMBL6516833 | 0.76 | — | — | |
| SCHEMBL838767 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932335-B2 | Pyrrolopyridine or pyrazolopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-04-03 | — | — | US | claimed |
| US-20160194321-A1 | PYRROLOPYRIDINE OR PYRAZOLOPYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-07-07 | — | — | US | claimed |
| EP-3039024-A1 | PYRROLOPYRIDINE OR PYRAZOLOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-07-06 | — | — | EP | claimed |
| WO-2015028483-A1 | PYRROLOPYRIDINE OR PYRAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-03-05 | — | — | WO | claimed |
| US-7563910-B2 | Heterocyclic cannabinoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-07-21 | — | — | US | claimed |
| EP-1749002-B1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | EP | claimed |
| EP-1749002-A1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-07 | — | — | EP | claimed |
| WO-2005108393-A1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-17 | — | — | WO | claimed |
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | US | claimed |
| CN-114671864-B | Heteroaryl substituted pyridines and methods of use | 艾伯维公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-114671864-A | Heteroaryl substituted pyridines and methods of use | 艾伯维公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-109311864-B | Heteroaryl substituted pyridines and methods of use | 艾伯维公司 | 2022-05-10 | — | — | CN | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| EP-3830080-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2021-06-09 | — | — | EP | disclosed |
| WO-2010033168-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| US-7563910-B2 | Heterocyclic cannabinoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1749002-B1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | EP | disclosed |
| EP-1749002-A1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005108393-A1 | PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-17 | — | — | WO | disclosed |
| US-20050250769-A1 | Heterocyclic cannabinoid receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | US | disclosed |